The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
Daratumumab and hyaluronidase-fihj received FDA approval for high-risk smoldering multiple myeloma, showing significant PFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback